——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA, September 19, 2011 [...]
Tag Archive > Molecular Diagnostics
Begleittest zur Erkennung von Patienten mit Melanommutation in Europa erhältlich
Pleasanton, Kalifornien (ots/PRNewswire) – – Test zur Bestimmung der cobas BRAF-Mutation erkennt Melanome, bei denen eine genetische Mutation vorliegt, die eine Behandlung mit Zelboraf (Vemurafenib) ermöglicht Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass der cobas BRAF-Mutationstest jetzt in Europa und anderen Ländern, die die CE-Kennzeichnung anerkennen, im Handel erhältlich ist. Der cobas [...]
Agendia Announces Launch of Initial Public Offering (IPO) on NYSE Euronext in Amsterdam
Amsterdam (ots/PRNewswire) – – Agendia Publishes Prospectus and Sets Indicative IPO Price Range – Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, into or in The United States, Australia, Canada, or Japan This announcement is not a prospectus but an advertisement and nothing herein contains an offering of securities. [...]
Der Blut-Screening Test, Der Sofortige Viral-Unterscheidungen Für Drei Wichtige Viren Bietet, Erhält Die CE-Kennzeichnung
Pleasanton, Kalifornien (ots/PRNewswire) – – Der cobas(R) TaqScreen MPX Test, v2.0(1) liefert Echtzeit-Resultate für HIV, HCV und HBV Roche (SIX: RO, ROG; OTCQX: RHHBY) kündigte heute an, dass der cobas(R) TaqScreen MPX Test, version 2.0 für den Einsatz auf dem cobas s 201-System ab jetzt in Europa im Handel erhältlich sei. Diese neueste Version des [...]
EANS-News: Epigenomics AG to Suggest Reduction of Share Capital and 5:1 Reverse Stock Split at Upcoming AGM
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Annual & Special Corporate Meetings/Company Information/molecular diagnostics Berlin, Germany, May 18, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today issued invitations to its Annual General Shareholders´ Meeting scheduled [...]
EANS-News: Epigenomics AG: Screening More People for Colorectal Cancer with Septin9 Blood Tests Could Provide Medical Benefit and Be Cost-Effective
Health economic analysis in favor of Septin9 testing presented by renowned Stanford University researcher at Digestive Disease Week 2011 Patient behavior study underway to demonstrate compliance benefit ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/molecular diagnostics Subtitle: Health economic analysis in favor [...]
EANS-News: Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Personnel/Molecular diagnostics Berlin, Germany, and Seattle, WA, USA, April 20, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive [...]
EANS-Adhoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 28.02.2011 Berlin, Germany, February 28, 2011 – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer [...]
EANS-News: Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing
QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Joint Ventures/Cooperation/Collaboration/New Products/Molecular diagnostics Subtitle: QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted [...]
EANS-News: Epigenomics Provides Update on Progress with US Product Development for Epi proColon
– Strong feasibility study data for improved product concept with 91% sensitivity and 87% specificity – FDA sets February date for Pre-IDE meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics Subtitle: – Strong feasibility study data for improved product concept [...]
EANS-News: Epigenomics Appoints Thomas Taapken as New CFO, Effective April 1, 2011
Brings significant U.S. experience and strategic transactions expertise ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Personnel/Molecular diagnostics Subtitle: Brings significant U.S. experience and strategic transactions expertise Berlin, Germany, and Seattle, WA, USA, January 11, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: [...]
EANS-News: Epigenomics AG Announces Hand-Over of CFO Responsibility by End of Q1 2011
Current CFO Oliver Schacht leaving by March 31, 2011; Experienced CFO Successor to join April 1st, 2011 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Personnel/Molecular diagnostics Subtitle: Current CFO Oliver Schacht leaving by March 31, 2011; Experienced CFO Successor to join April 1st, [...]
EANS-News: Warnex Launches Colorectal Cancer Blood Testing Service in Canada Using Epigenomics’ Septin9 Biomarker
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Berlin, Germany, and Laval, QC, Canada, December 6, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company and Warnex Medical Laboratories, a division of Warnex Inc. (TSX: [...]
EANS-News: Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Licensing Agreements/Company Information/Molecular diagnostics BERLIN, PHILADELPHIA, PA and LEXINGTON, MA, November 16, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel [...]
EANS-News: Epigenomics Signs Distribution Deal with DPC for Epi proColon in Middle East
Third distribution agreement for Epi proColon completes the picture for the Middle East ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Third distribution agreement for Epi proColon completes the picture for the Middle East BERLIN and SEATTLE, November 5, 2010 [...]
